Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention?

Saved in:
Bibliographic Details
Published inCirculation (New York, N.Y.) Vol. 109; no. 16; pp. e195 - 6; author reply e195-6
Main Author Beranek, Jiri T
Format Journal Article
LanguageEnglish
Published United States 27.04.2004
Subjects
Angioplasty, Balloon, Coronary
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Chemotherapy, Adjuvant
Complement C5 - antagonists & inhibitors
Complement C5 - immunology
Humans
Myocardial Infarction - drug therapy
Myocardial Infarction - pathology
Myocardial Infarction - therapy
Single-Chain Antibodies
Treatment Outcome
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:0009-7322
1524-4539
DOI:10.1161/01.cir.0000127111.19811.f9